RBC Capital raised the firm’s price target on Medtronic (MDT) to $118 from $111 and keeps an Outperform rating on the shares. The company delivered a 1.0% beat on sales and 3.8% on EPS in Q2, driven by accelerating cardiovascular performance, the analyst tells investors in a research note. RBC further cites Medtronic expecting similar growth in Q3 and to exit the FY at 6%, noting that its thesis of growth acceleration is playing out.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDT:
- Medtronic price target raised to $102 from $95 at UBS
- Medtronic price target raised to $109 from $103 at Baird
- Medtronic price target raised to $114 from $100 at Wells Fargo
- Cautious Hold Rating on Medtronic Amid Mixed Segment Performance and Uncertain Growth Prospects
- Medtronic price target raised to $111 from $98 at Bernstein